Juvenescence, which aims to increase its lifespan to 150 years shortly, raised $ 100 million in its latest fundraising campaign.
Founded in 2016, Juvenescence is the company that is creating a "longevism ecosystem". With world-renowned scientists, pharmacologists, machine learning experts and capable managers able to move safely in this booming biotech sector.
The latest press release from the company announces a $ 10 million loan from its founders and another $ 10 million apiece for 4 other investors. These include Grok Ventures, Mike Cannon-Brookes' investment company, and the private fund IPGL. The total raised by Juvenescence in the past 18 months is therefore $ 165 million, a figure that shows all the growth in interest in longevity medical treatments.
“Juvenescence has raised more funds than other similar companies, and it's good news for longevism. It is a reward for the skills of our team. It makes us believe even more in the opportunities we are testing in collaboration with scientists, entrepreneurs and research institutes, " says Jim mellon, one of the founders of Juvenescence.
“We have brought together a group of fantastic experts from around the world for our common mission to extend human life. As longevism becomes a known issue, we expect investor interest to rise. The next phase will be listing on the Juvenescence stock exchange to further accelerate its development. "
12 apostles of longevism: they will become 4 (or more) evangelists
The funds raised will be used to advance the various anti-aging programs, 12 of which are undergoing clinical trials. Of these, at least 4 will be on the market between 5 and 7 years from 2019.
Among them, many carry products that slow down cellular aging. Others reverse neurodegenerative processes or destroy senescent cells. Still others replace exhausted organs and edit patient genes.
"The past six months have been really exciting for Juvenescence," says the CEO Dr. Greg Bailey. “Extraordinary medical and IT professionals have joined the team, they will help us bring our therapies to the public. This new injection of funds will give us the capital necessary to fully develop our first solutions ".
Il longevism he gets more and more interest and money. The world anti-aging market is estimated at around $ 110 billion.